2024
EP.06D.04 Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer
Peleg A, de la Fuente R, Lichtman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Rohs N, Smith C, Rolfo C. EP.06D.04 Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s502-s503. DOI: 10.1016/j.jtho.2024.09.932.Peer-Reviewed Original ResearchP3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
de la Fuente R, Peleg A, Litchman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Smith C, Rohs N, Rolfo C. P3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s323. DOI: 10.1016/j.jtho.2024.09.579.Peer-Reviewed Original Research
2023
EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer
Desland F, Fitzgerald B, Sheppard R, Van Hyfte G, Shimkus M, Rohs N, Veluswamy R, Rolfo C, Marron T, Smith C, Gomez J, Doroshow D. EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2023, 18: s644. DOI: 10.1016/j.jtho.2023.09.1225.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerAdvanced EGFRPoor outcomeLung cancerPatientsOsimertinibCancerEGFR